252 related articles for article (PubMed ID: 19230928)
21. Smoking reduces the efficacy of intravesical bacillus Calmette-Guérin immunotherapy in non-muscle-invasive bladder cancer.
Rink M; Xylinas E; Babjuk M; Pycha A; Karakiewicz PI; Novara G; Dahlem R; Shariat SF
Eur Urol; 2012 Dec; 62(6):1204-6. PubMed ID: 22980442
[No Abstract] [Full Text] [Related]
22. [Management of Ta, T1, and in situ bladder carcinoma: what is new?].
Irani J
Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634
[TBL] [Abstract][Full Text] [Related]
23. Can random bladder biopsies be eliminated after bacillus Calmette-Guérin therapy against carcinoma in situ?
Takamatsu K; Matsumoto K; Kikuchi E; Ogihara K; Hayakawa N; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Asanuma H; Mikami S; Oyama M; Oya M
Int Urol Nephrol; 2021 Mar; 53(3):465-469. PubMed ID: 33025406
[TBL] [Abstract][Full Text] [Related]
24. Current state of immunotherapy for bladder cancer.
Kassouf W; Kamat AM
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1037-46. PubMed ID: 15606331
[TBL] [Abstract][Full Text] [Related]
25. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Böhle A; Brandau S
J Urol; 2003 Sep; 170(3):964-9. PubMed ID: 12913751
[TBL] [Abstract][Full Text] [Related]
26. Entrez into the immunogenetics of superficial bladder cancer response to bacillus Calmette-Guerin.
O'Donnell M
J Urol; 2006 Apr; 175(4):1197-8. PubMed ID: 16515958
[No Abstract] [Full Text] [Related]
27. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
28. Is intravesical bacillus Calmette-Guérin better than mitomycin for intermediate-risk bladder cancer?
Dalbagni G
Eur Urol; 2009 Aug; 56(2):257-8; discussion 258-9. PubMed ID: 19427109
[No Abstract] [Full Text] [Related]
29. [A comparative study of BCG and mitomycin C in superficial carcinomas of the bladder].
Iavarone C; Minocchi L; Arecchi S; Nicolucci D; Porcelli C; D'orazi V; Greco L; Stio F; Martino G; Messinetti S
G Chir; 1996 May; 17(5):289-91. PubMed ID: 8755233
[No Abstract] [Full Text] [Related]
30. The impact of the global bacille Calmette-Guérin shortage on treatment patterns: population-based data.
Perera M; Papa N; Christidis D; McGrath S; Manning T; Roberts M; Bolton D; Lawrentschuk N; Sengupta S
BJU Int; 2018 Feb; 121(2):169-172. PubMed ID: 29072817
[No Abstract] [Full Text] [Related]
31. Fibrin clot inhibitor medication and efficacy of bacillus Calmette-Guerin for bladder urothelial cancer.
Boorjian SA; Berglund RK; Maschino AC; Savage CJ; Herr HW
J Urol; 2009 Oct; 182(4):1306-12. PubMed ID: 19683284
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
33. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
34. [Systemic BCG reactions after intravesical BCG therapy. A report of four cases].
Sfaxi M; Langar H; Ouni A; Riahi Y; El Aidli S; Daghfous R; Ben Abdeladhim A; Chébil M
Therapie; 2008; 63(1):43-7. PubMed ID: 18387275
[TBL] [Abstract][Full Text] [Related]
35. Bacillus Calmette-Guérin versus mitomycin C for the treatment of intermediate-risk non-muscle-invasive bladder cancer: the debate continues.
Sylvester RJ
Eur Urol; 2009 Aug; 56(2):266-8; discussion 268-9. PubMed ID: 19427110
[No Abstract] [Full Text] [Related]
36. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
37. Re: Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Palou J; Rodríguez O; Segarra J; Rosales A
J Urol; 2006 Jul; 176(1):407; author reply 407-8. PubMed ID: 16753451
[No Abstract] [Full Text] [Related]
38. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward?
Zuiverloon TC; Zwarthoff EC
Eur Urol; 2016 Feb; 69(2):201-2. PubMed ID: 26209036
[No Abstract] [Full Text] [Related]
39. Words of wisdom. Re: prognostic factors and risk groups in T1G3 non–muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
Lotan Y
Eur Urol; 2014 Nov; 66(5):968-9. PubMed ID: 25763447
[No Abstract] [Full Text] [Related]
40. Re: Amit R. Patel, Edmund S. Sabanegh, J. Stephen Jones, et al. Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol 2010;58:934-7.
Oliveira CA; Rodríguez O; Palou J; Palou-Redorta J
Eur Urol; 2011 Jul; 60(1):e7. PubMed ID: 21531073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
